The systemic vasculitides are a group of diseases characterized by severe inflammation of blood vessels leading to arterial stenosis or occlusion, and organ damage or death if untreated. With aggressive immunosuppressive treatment, most patients survive, but subsequent disease course is variable, relapse is common, and long-term morbidity from vasculitis or its treatment is expected. Long-term longitudinal studies are needed to inform and guide clinicians in this era of adequate but imperfect management. There are also significant unmet needs for i) biomarkers of disease activity, risk of relapse, and long-term damage;ii) genetic epidemiology studies to provide insight into pathogenesis and ideas for therapeutics;iii) early-phase clinical trials of novel therapeutics;iv) novel methods to conduct high-quality clinical trials and clinical research studies in these rare diseases;and v) for improved outcome measures, including patient-reported outcomes. The VCRC Longitudinal Studies address all these unmet needs through the multiple research studies associated with these protocols. The Vasculitis Clinical Research Consortium, initiated in 2004 under the auspices of the NIH Rare Diseases Clinical Research Network (RDCRN), encompasses longitudinal cohort studies of six vasculitides [giant cell arteritis (GCA), Takayasu's arteritis (TAK), polyarteritis nodosa (PAN), granulomatosis with polyangiitis (Wegener's, GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (Churg- Strauss, EGPA)] at leading referral centers in the US and Canada. More than 5000 patients have been enrolled. The VCRC Longitudinal Studies are central to the goals of this RDCRC and serve as the foundation for the exploration of new potential biomarkers of disease, phase II and 111 clinical trials, development of improved outcome measures, training of fellows in vasculitis research, and collaboration with patient support organizations.
The Specific Aims of this project are to 1) support the continued successful conduct of the VCRC Longitudinal Studies of six vasculitides, 2) expand the Longitudinal Studies to include patients with isolated aortitis, and 3) maintain and expand the VCRC Biospecimen and Clinical Data Repositories for use by a broad range of scientists, both within and beyond the core group of Consortium investigators.

Public Health Relevance

The Vasculitis Clinical Research Consortium (VCRC) is an extensive infrastructure that allows experts in multiple centers to collaborate on research in vasculitis, a group of rare and serious diseases that feature inflammatory destruction of blood vessels. The VCRC Longitudinal Studies, in which clinical information on patients is collected for up to 10 years, serve as the foundation for the Consortium's many clinical research studies and clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54AR057319-12
Application #
8909276
Study Section
Special Emphasis Panel (ZTR1-CI-8 (01))
Program Officer
Wang, Yan Z
Project Start
2014-09-01
Project End
2019-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
12
Fiscal Year
2014
Total Cost
$570,453
Indirect Cost
$111,937
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Hatemi, Gulen; Merkel, Peter A; Hamuryudan, Vedat et al. (2014) Outcome measures used in clinical trials for Beh├žet syndrome: a systematic review. J Rheumatol 41:599-612
Monach, Paul A (2014) Biomarkers in vasculitis. Curr Opin Rheumatol 26:24-30
Grayson, Peter C; Amudala, Naomi A; McAlear, Carol A et al. (2014) Causal attributions about disease onset and relapse in patients with systemic vasculitis. J Rheumatol 41:923-30
Merkel, Peter A; Aydin, Sibel Z; Boers, Maarten et al. (2014) Current status of outcome measure development in vasculitis. J Rheumatol 41:593-8
Mooney, Janice; Spalding, Nicola; Poland, Fiona et al. (2014) The informational needs of patients with ANCA-associated vasculitis-development of an informational needs questionnaire. Rheumatology (Oxford) 53:1414-21
Langford, Carol A; Monach, Paul A; Specks, Ulrich et al. (2014) An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis 73:1376-9
Kermani, Tanaz A; Warrington, Kenneth J; Crowson, Cynthia S et al. (2013) Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis 72:1989-94
Monach, Paul A; Warner, Roscoe L; Tomasson, Gunnar et al. (2013) Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Ann Rheum Dis 72:1342-50
Schmidt, Jean; Kermani, Tanaz A; Bacani, A Kirstin et al. (2013) Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients. Mayo Clin Proc 88:822-30
Grayson, Peter C; Amudala, Naomi A; Mcalear, Carol A et al. (2013) Illness perceptions and fatigue in systemic vasculitis. Arthritis Care Res (Hoboken) 65:1835-43

Showing the most recent 10 out of 37 publications